BiotechTube
Heranova Lifesciences

Heranova Lifesciences

Cambridge, United States· Est.
heranova.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Heranova Lifesciences is a private, early-stage diagnostics company targeting significant unmet needs in women's health. The company has launched its first commercial product, HerResolve™, a non-invasive blood test for the detection and confirmation of endometriosis, which is being rolled out at select US fertility clinics. Heranova is positioned in a large and underserved market, aiming to reduce the diagnostic delay for endometriosis and improve fertility treatment planning. The company appears to be in an early revenue-generating phase as it commercializes its initial test while developing a broader pipeline of diagnostics and potential treatments.

EndometriosisFemale Infertility

Technology Platform

Platform for developing non-invasive, blood-based diagnostic tests for women's health conditions, starting with endometriosis.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The massive, underserved market for endometriosis diagnostics, with an average 6-12 year diagnostic delay, presents a prime opportunity for a non-invasive test.
Success in the fertility clinic channel provides a direct path to a motivated patient population and can serve as a springboard into the broader gynecology and primary care markets.

Risk Factors

Key risks include the need to prove the long-term clinical utility and cost-effectiveness of HerResolve™ to secure widespread payer reimbursement.
The company also faces competition from potential new market entrants and must successfully scale its commercial operations from a limited launch to a broader market.

Competitive Landscape

The non-invasive endometriosis diagnostic space is emerging but not yet crowded. Competition may come from other startups developing blood or imaging-based tests, as well as from large diagnostic companies that could enter the market. Heranova's first-mover advantage with a commercially available test in the US fertility setting is a current differentiator.

More companies in United States →